17th February 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Mankind Pharma to Purchase DRL's brand Combihale and Daffy

While Combihale is indicated for the treatment of patients with asthma and COPD, Daffy is a soap-free moisturising bar for babies.

Macleods Pharma to Raise Rs.5000 cr

The drug company has filed preliminary papers with the Securities and Exchange Board of India to mop-up Rs.5000 cr through Initial Public Offerings.

FDA Approves Generic Lamotrigine ODT

The US’s drug regulator has granted approval to Amring Pharma for its generic lamotrigine ODT.

AtHeart Medical receives FDA nod for second phase of ASD occluder IDE study

AtHeart Medical is examining the safety and efficacy of the reSept Atrial Septal Defects (ASD) occluder in a prospective, single-arm clinical study.

USFDA Okays LEXEO Therapeutics Investigational New Drug (IND) application for LX2006

LX2006 is developed to intravenously deliver a functional frataxin gene, for the treatment of patients with Friedreich’s ataxia cardiomyopathy.

Tandem Diabetes Care Scores FDA Approval for Insulin App

tconnect mobile app is the first smartphone app for insulin delivery on major OS platforms.

Drug Regulator Grants Breakthrough Device Designation to ctDNA Tracker

The assay is designed to detect ctDNA in plasma cells and optimize algorithms for identifying patientspecific variants.

Accord Healthcare launches Additional Strengths of Hydroxychloroquine Sulfate tablets

Hydroxychloroquine is the generic version of Plaquenil and is primarily used to treat patients suffering from rheumatoid arthritis, lupus and malaria.

Certara Customers Obtains 90% of FDA New Drug Approvals

Certara declared that 90% of novel drugs by the FDA’s CDER were received by Certara customers in 2021.

USFDA Okays phase 2b/3 Trial of Adult Attention Deficit Hyperactivity Disorder Treatment

Neurocentria a late-stage biotech company has received approval to initiate a pivotal phase 2b/3 clinical trial of its NRCT-101SR compared with inactive placebo among adult patients with ADHD.